论文部分内容阅读
作者及其它学者发现急性早幼粒细胞白血病(APL)凝血异常是因纤维蛋白溶解增强.它与α_2-抗纤溶酶缺乏及其转换率增高相关,先天性α_2-抗纤溶酶缺乏的特征是严重出血,能被反式-胺甲基-环六烷基甲酸(Tranexamic acid(TA))有效地预防,TA是一种特异性抗纤维蛋白溶解剂.故作者设计随机双盲对照试验来评价TA治疗APL的临床效果及减少出血和输血的安全性.
The authors and others found that coagulation abnormalities in acute promyelocytic leukemia (APL) are due to an increase in fibrinolysis, which is related to an increase in α_2-antiplasmin and its conversion rate, a congenital deficiency of α_2-antiplasmin Is a severe hemorrhage and can be effectively prevented by trans-aminomethyl-tranexamic acid (TA), a specific anti-fibrinolytic agent. Therefore, the authors designed a randomized, double-blind, controlled trial Evaluate the clinical efficacy of TA in the treatment of APL and reduce the safety of bleeding and transfusion.